Evaluation of perioperative routine coagulation testing versus thromboelastography for major liver resection – A single-arm, prospective, interventional trial (PORTAL trial) DOI Creative Commons
Reshma Ambulkar, V. Baskar, Shraddha Patkar

и другие.

Indian Journal of Anaesthesia, Год журнала: 2023, Номер 67(12), С. 1077 - 1083

Опубликована: Дек. 1, 2023

Background and Aims: The International Normalised Ratio (INR), which assesses the loss of procoagulant factors in extrinsic pathway, fails to evaluate coagulation abnormalities comprehensively after a major liver resection, often leads reduced synthesis anticoagulant-factors. This study was conducted with an aim trend compare results routine tests thromboelastography (TEG) during perioperative period patients undergoing resections (≥3 segments). Methods: Twenty-five who underwent resection were enrolled. prospective, single-arm, interventional performed primary objective determining serial changes conventional TEG resections, at preincision period, intraoperative postoperatively, 48 h on fifth postoperative day. Transfusion requirements blood components also assessed TEG-guided replacement strategy. Spearman rank-order correlation used relationships (both tests) each time point. Results: prothrombin (PT)-INR elevated 14 (56%) intraoperative, immediate 48-h points contrast parameters, remained normal all patients. Blood component transfusion avoided 4, 11 10 points, respectively. Conclusion: overestimates coagulopathy thromboelastography-guided strategy reduces overall requirements.

Язык: Английский

Unraveling breast cancer prognosis: a novel model based on coagulation-related genes DOI Creative Commons

Chuqi Lei,

Yuan Li, Huaiyu Yang

и другие.

Frontiers in Molecular Biosciences, Год журнала: 2024, Номер 11

Опубликована: Май 1, 2024

Objective Breast cancer is highly heterogeneous, presenting challenges in prognostic assessment. Developing a universally applicable model could simplify clinical decision-making. This study aims to develop and validate novel breast prognosis using coagulation-related genes with broad applicability. Methods A total of 203 related coagulation were obtained from the KEGG database, mRNA data 1,099 tumor tissue samples 572 normal retrieved TCGA-BRCA cohort GTEx databases. The R package “limma” was utilized detect variations gene expression between malignancies tissue. constructed TCGA through multivariable Cox regression analysis, followed by validation GSE42568 dataset as testing set. Constructing nomogram incorporating factors enhance predictive capacity model. Utilizing ESTIMATE algorithm investigate immune infiltration levels groups deferent risk. Performing drug sensitivity analysis “oncoPredict” package. Results risk consisting six coagulation-associated (SERPINA1, SERPINF2, C1S, CFB, RASGRP1, TLN2) created successfully tested for validation. Identified 6 that serve protective model’s development. Kaplan-Meier curves revealed worse high-risk group compared low-risk group. ROC showed accurately forecasted overall survival (OS) patients at 1, 3, 5 years. Nomogram accompanied calibration can also provide better guidance more likely respond well immunotherapy, whereas may show improved responses Gemcitabine treatment. Furthermore, individuals distinct categories displayed different various medications within identical therapeutic category. Conclusion We established explored its utility. offers valuable insights decision-making selection patients, contributing personalized precise treatment advancements.

Язык: Английский

Процитировано

4
Systemic coagulation activation in patients with glioblastoma DOI Creative Commons

Justyna Rybus,

Sandra A Pilawska,

Magdalena Dębicka

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Март 31, 2025

Abstract Purpose To assess if patients diagnosed with glioblastoma have higher markers of systemic coagulation activation in thrombin generation assay (TGA) and blood tests. Methods We collected preoperative samples from 42 35 healthy controls. assessed fibrinogen concentration, degradation products (FDP) D-dimer concentrations, plasminogen activator inhibitor concentration (PAI:Ag), antithrombin (AT) activity, thrombin-antithrombin complexes (TAT), the peak (P), endogenous potential (ETP), Lag Time Peak (TTP). Results Patients showed values following parameters preoperatively such as (1.8 ± 3.6 vs 0.35 0.32 mg/l, p = 0.02), PAI:Ag (27.30 8.90 17.00 9.34, < 0.01) TAT (15.20 4.56 1.66, 0.01). Furthermore they longer (3.50 1.00 3.02 0.69, TTP (6.60 1.50 5.73 1.04, TGA. Conclusion High d-dimer, PAI:AG concentrations are prothrombotic but did not indicate increased activity. The above information sheds new light on disorders patients. This may also that TGA by calibrated automated thrombogram (CAT) has limited ability to detect subtle abnormalities system. In both situations further studies required.

Язык: Английский

Процитировано

0
Targeting EGFR-TKI resistance in lung cancer: Role of miR-5193/miR-149-5p loaded NK-EVs and Carboplatin combination DOI
Aakash Nathani, Li Sun, Yan Li

и другие.

International Journal of Pharmaceutics, Год журнала: 2025, Номер 675, С. 125573 - 125573

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
The role of thrombin in the paradoxical interplay of cancer metastasis and the vascular system: A driving dynamic DOI
Özge Bayrak, Meltem Alper, Yasemin Başbınar

и другие.

Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 186, С. 118031 - 118031

Опубликована: Апрель 10, 2025

Язык: Английский

Процитировано

0
Challenges and Opportunities of Direct Oral Anticoagulant (DOAC) Therapy in Complex Clinical Scenarios: A Comprehensive Review and Practical Guide DOI Open Access
Giuseppe Miceli, Anna Maria Ciaccio, Antonino Tuttolomondo

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(9), С. 2914 - 2914

Опубликована: Апрель 23, 2025

Direct oral anticoagulants (DOACs) have emerged as a preferred alternative to vitamin K antagonists (VKAs) for the prevention and treatment of thromboembolic disorders, offering improved safety, predictable pharmacokinetics, ease administration. Despite these advantages, their use in complex clinical scenarios presents significant challenges that necessitate individualized therapeutic strategies. This comprehensive review explores efficacy, limitations DOAC therapy special populations, including patients with renal or hepatic impairment, obesity, cancer-associated thrombosis, antiphospholipid syndrome. Additionally, we examine role uncommon thrombotic conditions such superficial venous embolic stroke undetermined source, upper extremity vein inferior vena cava pelvic cerebral thrombosis. The pharmacokinetic variability DOACs dysfunction requires caution balance bleeding risks. In altered drug distribution metabolism raise concerns regarding appropriate dosing efficacy. Cancer-associated thrombosis interplay prothrombotic mechanisms, necessitating careful selection anticoagulant therapy. Furthermore, syndrome remains controversial due about recurrent events. Finally, some unusual like cava, vein, has scarce evidence. aims guide clinicians optimizing anticoagulation management challenging patient populations by synthesizing current evidence providing practical recommendations.

Язык: Английский

Процитировано

0
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade DOI Open Access
Andriani Charpidou, Grigoris Gerotziafas, Sanjay Popat

и другие.

Cancers, Год журнала: 2024, Номер 16(2), С. 450 - 450

Опубликована: Янв. 20, 2024

Cancer-associated thrombosis (CAT) is a common complication in lung cancer patients. Lung confers an increased risk of compared to other solid malignancies across all stages the disease. Newer treatment agents, including checkpoint immunotherapy and targeted may further increase CAT. Different risk-assessment models, such as Khorana Risk Score, newer approaches that incorporate genetic factors have been used patients evaluate thrombosis. The management CAT based on results large prospective trials, which show similar benefits low-molecular-weight heparins (LMWHs) direct oral anticoagulants (DOACs) ambulatory anticoagulation agent duration therapy should be personalized according stage histology, presence driver mutations use antineoplastic therapy, recent curative surgery, chemotherapy or immunotherapy. Treatment options evaluated context COVID-19 pandemic, has shown impact thrombotic This review focuses epidemiology, pathophysiology, factors, novel predictive scores with active cancer, focus immune inhibitors.

Язык: Английский

Процитировано

3
Stromal Fibrin Shapes Immune Infiltration Landscape of Pancreatic Ductal Adenocarcinoma DOI
Mazharul Karim, Md. Mahedi Hasan, Seung Hyun Kim

и другие.

Biomaterials, Год журнала: 2025, Номер unknown, С. 123280 - 123280

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Unravelling Cancer Immunity: Coagulation.Sig and BIRC2 as Predictive Immunotherapeutic Architects DOI Creative Commons

Ziang Yao,

Jun Fan,

Yucheng Bai

и другие.

Journal of Cellular and Molecular Medicine, Год журнала: 2025, Номер 29(7)

Опубликована: Март 30, 2025

ABSTRACT Immune checkpoint inhibitors (ICIs) represent a groundbreaking advancement in cancer therapy, substantially improving patient survival rates. Our comprehensive research reveals significant positive correlation between coagulation scores and immune‐related gene expression across 30 diverse types. Notably, tumours exhibiting high demonstrated enhanced infiltration of cytotoxic immune cells, including CD8 + T natural killer (NK) macrophages. Leveraging the TCGA pan‐cancer database, we developed Coagulation.Sig model, sophisticated predictive framework utilising coagulation‐related genes (CRGs) to forecast immunotherapy outcomes. Through rigorous analysis ten ICI‐treated cohorts, identified validated seven critical CRGs: BIRC2, HMGB1, STAT2, IFNAR1, BID, SPATA2, IL33 IFNG, which form foundation our model. Functional analyses revealed that low‐risk characterised by higher cell populations, particularly superior ICI responses. These also exhibited increased mutation rates, elevated neoantigen loads, greater TCR/BCR diversity. Conversely, high‐risk displayed pronounced intratumor heterogeneity (ITH) NRF2 pathway activity, mechanisms strongly associated with evasion. Experimental validation highlighted BIRC2 as promising therapeutic target. Targeted knockdown, when combined anti‐PD‐1 significantly suppressed tumour growth, infiltration, amplified IFN‐γ TNF‐α secretion models. findings position model novel, approach personalised treatment, emerging both biomarker potential intervention point.

Язык: Английский

Процитировано

0
Divalent cations and SERPIN gene expression modulate horseshoe crab coagulation under LPS induction DOI

Xinn Xian Kwong,

Fisal Ahmad,

Cheng Tzi Him

и другие.

Journal of Immunological Methods, Год журнала: 2025, Номер unknown, С. 113866 - 113866

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Efficacy of mFOLFOX6 plus bevacizumab regimen in advanced colorectal cancer after deep hyperthermia: a single-center retrospective study DOI Creative Commons

Guohu Han,

Lihua Cui, Changchun Sun

и другие.

Frontiers in Oncology, Год журнала: 2023, Номер 13

Опубликована: Дек. 5, 2023

This study aimed to explore the clinical efficacy and safety of a modified FOLFOX6 (oxaliplatin + leucovorin 5-fluorouracil) plus bevacizumab regimen after deep hyperthermia in advanced colorectal cancer.A total 80 cancer patients treated at our hospital were selected as research subjects. According random number table method, divided into control group (mFOLFOX6 bevacizumab) combination treatment), with 40 each group. After six cycles treatment, objective response rate (ORR), disease (DCR), levels serum tumor markers carcinoembryonic antigen (CEA), vascular epidermal growth factor (VEGF), Karnofsky performance status (KPS) scores, occurrence adverse events compared between two groups.After ORR was higher than that group, but difference not statistically significant (P>0.05). The DCR significantly (P<0.05). CEA groups treatment lower those before VEGF (all P<0.001). KPS scores both incidence fatigue pain (P<0.05).mFOLFOX6 is effective patients, which can effectively improve their quality life, are controllable tolerable. A randomized or prospective trial will be required further prove these data its potentiality, especially if conventional treatment.

Язык: Английский

Процитировано

1